Skip to main content

Advertisement

SpringerLink
Log in

The Role of Peri-operative Chemotherapy for Resectable Colorectal Liver Metastasis: What Does the Evidence Support?

  • SSAT/AHPBA Joint Symposium 2010
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239(6):818–25; discussion 25–7.

    Google Scholar 

  2. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235(6):759–66.

    Article  PubMed  Google Scholar 

  3. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241(5):715–22, discussion 22–4.

    Google Scholar 

  4. de Jong MC, Mayo SC, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 2009; 13(12):2141–51.

    Article  PubMed  Google Scholar 

  5. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250(3):440–8.

    PubMed  Google Scholar 

  6. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25(29):4575–80.

    Article  PubMed  Google Scholar 

  7. Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol 2010; 28(13):2300–9.

    Google Scholar 

  8. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27(6):872–7.

    Article  PubMed  Google Scholar 

  9. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350(23):2343–51.

    Article  PubMed  CAS  Google Scholar 

  10. Wolmark N, Wieand S, Kuebler PJ, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol 2008; 26(May 20 suppl):abstr LBA4005.

  11. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27(19):3109–16.

    Article  PubMed  CAS  Google Scholar 

  12. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22(18):3766–75.

    Article  PubMed  CAS  Google Scholar 

  13. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355(9209):1041–7.

    Article  PubMed  CAS  Google Scholar 

  14. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22(2):229–37.

    Article  PubMed  CAS  Google Scholar 

  15. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22(1):23–30.

    Article  PubMed  CAS  Google Scholar 

  16. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005; 104(2):282–9.

    Article  PubMed  CAS  Google Scholar 

  17. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12):2013–9.

    Article  PubMed  CAS  Google Scholar 

  18. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20(11):1842–7.

    Article  PubMed  Google Scholar 

  19. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360(14):1408–17.

    Article  PubMed  Google Scholar 

  20. O'Connell MJ, Adson MA, Schutt AJ, et al. Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver. Mayo Clin Proc 1985; 60(8):517–20.

    PubMed  Google Scholar 

  21. Langer B, Bleiber H, Labianca R. Fluorouracil (FU) plus I-leucovorin (I-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): Results of the ENG (EORTC/NICC CTG/GIVIP) randomized trial. Proc Amer Soc Clin Oncol 2002; 21:149a.

    Google Scholar 

  22. Lopez-Ladron A, Salvador J, Bernabe B. Observation versus postoperative chemotherapy after resection of liver metastases in patients with advanced colorectal cancer. Proc Amer Soc Clin Oncol 2003; 22:373.

    Google Scholar 

  23. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24(31):4976–82.

    Article  PubMed  CAS  Google Scholar 

  24. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26(30):4906–11.

    Article  PubMed  CAS  Google Scholar 

  25. Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007; 204(5):753–61; discussion 61–3.

    Google Scholar 

  26. Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum 2007; 50(4):478–88.

    Article  PubMed  Google Scholar 

  27. Wang X, Hershman DL, Abrams JA, et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer 2007; 97(12):1606–12.

    Article  PubMed  CAS  Google Scholar 

  28. Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20(12):1964–70.

    Article  PubMed  CAS  Google Scholar 

  29. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009; 20(4):674–80.

    Article  PubMed  CAS  Google Scholar 

  30. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25(23):3456–61.

    Article  PubMed  CAS  Google Scholar 

  31. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1):11–20.

    Article  PubMed  CAS  Google Scholar 

  32. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371(9617):1007–16.

    Article  PubMed  CAS  Google Scholar 

  33. Muratore A, Ribero D, Zimmitti G, et al. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol; 17(5):1324–9.

  34. Parikh AA, Gentner B, Wu TT, et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003; 7(8):1082–8.

    Article  PubMed  Google Scholar 

  35. Gallagher DJ, Zheng J, Capanu M, et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009; 16(7):1844–51.

    Article  PubMed  Google Scholar 

  36. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240(6):1052–61; discussion 61–4.

    Google Scholar 

  37. Blazer DG, 3 rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26(33):5344–51.

    Article  PubMed  Google Scholar 

  38. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24(13):2065–72.

    Article  PubMed  CAS  Google Scholar 

  39. Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11(7):860–8.

    Article  PubMed  Google Scholar 

  40. Sahajpal A, Vollmer CM, Jr., Dixon E, et al. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol 2007; 95(1):22–7.

    Article  PubMed  CAS  Google Scholar 

  41. Scoggins CR, Campbell ML, Landry CS, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 2009; 16(1):35–41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Johns Hopkins University School of Medicine, Harvey 611, 600N Wolfe Street, Baltimore, MD, 21287, USA

    Timothy M. Pawlik

  2. Department of Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA

    David Cosgrove

Authors
  1. Timothy M. Pawlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Cosgrove
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy M. Pawlik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pawlik, T.M., Cosgrove, D. The Role of Peri-operative Chemotherapy for Resectable Colorectal Liver Metastasis: What Does the Evidence Support?. J Gastrointest Surg 15, 410–415 (2011). https://doi.org/10.1007/s11605-011-1423-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-011-1423-z

Keywords

Search

Navigation